Trovagene Inc. (NASDAQ:TROV) shares traded up 1.7% during mid-day trading on Friday . The stock traded as high as $4.89 and last traded at $4.87, with a volume of 105,210 shares. The stock had previously closed at $4.79.

Several research analysts have issued reports on the company. Cantor Fitzgerald lowered Trovagene from a “buy” rating to a “hold” rating and cut their price target for the stock from $9.00 to $5.00 in a report on Monday, April 25th. Piper Jaffray Cos. lowered Trovagene from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $5.26 to $8.00 in a report on Monday, April 25th. Maxim Group reiterated a “buy” rating on shares of Trovagene in a report on Monday, June 6th. Avondale Partners reiterated a “market perform” rating and issued a $6.00 price target on shares of Trovagene in a report on Tuesday, March 29th. Finally, Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $6.96.

The firm’s 50-day moving average price is $4.78 and its 200-day moving average price is $4.78. The company’s market cap is $150.80 million.

Trovagene (NASDAQ:TROV) last released its earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. Equities research analysts forecast that Trovagene Inc. will post ($1.30) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.